Overview

AG vs mFOLFIRINOX as Neoadjuvant Therapy for Borderline Reseactable and Locally Advanced Pancreatic Cancer

Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a prospective, single-center, randomized, controlled phase Ⅲ study.
Phase:
Phase 3
Details
Lead Sponsor:
Fudan University
Treatments:
Folfirinox
Gemcitabine
Paclitaxel